Entecavir는 비대상성 간경변 환자에서 안전하게 간기능을 호전시켰다. INR이 엔테카비어 치료 효과를 예측할 수 있는 인자로 관찰되었다.
참고 문헌
1. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-1010, 2006
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73, 2006
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341: 1256-1263, 1999 4. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E: Effect of
hepatitis B and C virus infections on the natural history of compensated cirrhosis:
a cohort study of 297 patients. Am J Gastroenterol 97: 2886-2895, 2002
5. Ganem D, Prince AM: Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004
6. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104:
1116-1121, 1993
7. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS: Management of hepatitis B:
summary of a clinical research workshop. Hepatology 45: 1056-1075, 2007
8. Jung SR, Suh DJ, Park HJ, Park YH, Song HG, Lee HC, Chung YH, Lee YS:
Therapeutic Efficacy of Lamivudine in Patients With Hepatitis B Virus-Related Decompensated Cirrhosis in Korea. Korean J Hepatol. 4: 418-427, 2002
9. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK: Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33: 308-312, 2000
10. Keeffe EB: End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. J Med Virol 61: 403-408, 2000
11. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4: 936-962, 2006
-19-
12. Kim JI, Na JS, Bang CS, Park SH, Han JY, Suh JM, Kim JK, Lee YS, Chung KW, Sun HS: Study of Long Term Follow - up of Interferon Therapy in Chronic Viral Hepatitis - in 222 cases during 127 weeks -. Korean J Hepatol 6: 241-251, 1997 13. Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M: Extension of
transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 69: 2382-2383, 2000 Wilber R, Zink RC, Cross A, Colonno R, Fernandes L: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1020, 2006
16. Lee WM: Hepatitis B virus infection. N Engl J Med 337: 1733-1745, 1997
17. Leung N: Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2: 163-178, 2008
18. Liaw YF: Results of lamivudine trials in Asia. J Hepatol 39 Suppl 1: S111-115, 2003 19. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH,
Omata M: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25: 472-489, 2005
20. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER: Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62-72, 2011
21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531, 2004 22. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E,
Bodicky C, Miller B, Denham C, et al.: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.
Gastroenterology 109: 908-916, 1995
23. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A: An international
collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 80: 63-71, 2001
24. Schiff ER: Prevention of mortality from hepatitis B and hepatitis C. Lancet 368:
896-897, 2006
25. Shaw T, Bartholomeusz A, Locarnini S: HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44: 593-606, 2006
26. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ: Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.
J Hepatol 52: 176-182, 2010
27. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: 1503-1514, 2009
28. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Hepatology 31: 207-210, 2000
29. Yao FY, Bass NM: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 33: 301-307, 2000 30. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM: Lamivudine treatment is
beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34: 411-416, 2001
31. Yeon JE, Seo YS, Kim YH, Park SH, Kwon OS, Byun KS, Lee CH: Long-term Follow-up of Patients Treated with Interferon Alfa for Chronic Hepatitis B. Korean J Hepatol 5: 12-21, 1999
-21-
- ABSTRACT –
Entecavir Therapy for Patients with Hepatitis B Virus-Related Decompensated Cirrhosis
decompensated cirrhosis. We evaluated efficacy of ETV in these patients with 12 months of therapy and what predictive factors of response are.Methods: Forty-five consecutive decompensated cirrhotic patients who received ETV (0.5mg/day) for more than six months were included. All patients were HBV DNA positive, and the Child–Turcotte–Pugh (CTP) scores were over 8 points. Seventeen patients were HBeAg-positive. CTP score, model for end-stage liver disease (MELD) score, serum markers of liver function and HBV DNA were assessed every 3 months.
Results: ETV treatment for 12 months resulted in improved CTP and MELD scores. Pre-treatment mean CTP and MELD score were decreased from 10.1 (±2.0), 13.48 (±4.05) to 7.24 (±2.0), 9.68(±4.85) at 12th months, respectively. The 1-year cumulative rates of HBV DNA negativity and HBeAg loss were 88.9% and 52.9%, respectively, by intention-to-treat analysis. Thirty-two (71.1%) showed improvement in Child-Pugh score. 11 patients had no change, and 2 patients got worse. The AST/ALT, albumin, bilirubin, prothrombin time were significantly normalized within six months. Improvement group, defined as a decrease in CPT score of ≥2 had high level of prothrombin time than other patients group.(p=0.004)
Conclusion: We suggest that entecavir can result in clinical improvement of liver function in about 70% of patients with HBV related decompensated liver cirrhosis. However, we did not find predictive factors of entecavir efficacy in these patients.
Key words: Entecavir, Liver cirrhosis, HBV DNA
-23-